Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

ADIL

Adial Pharmaceuticals Inc

NASDAQ

2.170

-0.150

-6.47%

After Hours: 2.150 -0.02 -0.92% 19:32 04/18 EDT

OPEN

2.300

PREV CLOSE

2.320

HIGH

2.300

LOW

2.120

VOLUME

153.63K

TURNOVER

52 WEEK HIGH

14.00

52 WEEK LOW

0.7650

MARKET CAP

8.80M

P/E (TTM)

-0.6034

ADIAL PHARMACEUTICALS INC FILES FOR COMMON STOCK OFFERING OF UP TO $4.3 MLN - SEC FILING

Reuters · 23h ago

12 Health Care Stocks Moving In Wednesday's Intraday Session

INVO Bioscience stock rose 275.0% to $2.85 during Wednesday's regular session. The company's Q4 earnings report came out yesterday. Vanda Pharma stock moved upwards by 33.33% during the session. Losers include Longeveron (NASDAQ:LGVN) and Dare BiosScience.

Benzinga · 2d ago

Adial Pharmaceuticals Announces CMO’s Departure and Leadership Changes

TipRanks · 3d ago

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. The company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome. Soligenix, Inc. Shares surged 71.5% after the company was granted orphan drug designation for MarVax.

Benzinga · 4d ago

Marinus Pharmaceuticals, Cartesian Therapeutics, Adial Pharmaceuticals among healthcare movers

Healthcare On the Move Marinus Pharmaceuticals, Cartesian Therapeutics, Adial Pharmaceuticals among healthcare movers. S&P 500 Health Care Sector +0.99% to 1634.94. Health Care Equipment & Services +1.15% to 1905.2.

Seeking Alpha · 4d ago

Weekly Report: what happened at ADIL last week (0408-0412)?

Weekly Report · 4d ago

Adial Pharmaceuticals files to sell 2.37M common shares for holders

Healthcare Adial Pharmaceuticals files to sell 2.37M common shares for holders Apr. 12, 2024 4:35 PM ET. Adial pharmaceuticals, Inc. Filed a prospectus related to the proposed resale of 2.38 million common shares by the selling stockholders.

Seeking Alpha · 04/12 20:35

ADIAL PHARMACEUTICALS- FILES PROSPECTUS RELATES TO RESALE FROM TIME TO TIME OF UP TO 2.36 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS

Reuters · 04/12 20:25

About ADIL

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. The Company’s drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder (AUD). AD04 is used for the treatment of AUD in subjects with certain target genotypes, which were identified using its companion diagnostic genetic test. AD04 is a genetically targeted, serotonin-3 receptor antagonist, a therapeutic agent for the treatment of AUD. The Company’s AD04 also has the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders.

Webull offers Adial Pharmaceuticals Inc stock information, including NASDAQ: ADIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADIL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADIL stock methods without spending real money on the virtual paper trading platform.